Share This Article:

STYK1/NOK—A Potential Radiotherapeutic Target and Biomarker for Gastric Cancer and Cervical Cancer

Abstract Full-Text HTML XML Download Download as PDF (Size:95KB) PP. 575-577
DOI: 10.4236/jct.2013.42073    2,851 Downloads   4,383 Views   Citations

ABSTRACT

This article introduced the STYK1/NOK, including its origin, chemical composition and biological function, and the expression of STYK1/NOK in various cancer cell lines was reviewed. Furthermore, our recent study showed that STYK1/NOK protein was also over expressed in gastric cancer and cervical cancer specimens, and STYK1/NOK expression increased after tumor cells were irradiated with γ ray. These results indicated that STYK1/NOK might be involved in the occurrence and progress of gastric cancer and cervical cancer, and contribute to the radioresistance of tumor cells. Thus, STYK1/NOK might be a potential therapeutic target and diagnostic marker for gastric cancer and cervical cancer.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

L. Gao, X. Chen, Z. Ma and F. Li, "STYK1/NOK—A Potential Radiotherapeutic Target and Biomarker for Gastric Cancer and Cervical Cancer," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 575-577. doi: 10.4236/jct.2013.42073.

References

[1] L. Liu, X. Z. Yu, T. S. Li, L. X. Song, P. L. Chen, T. L. Suo, Y. H. Li, S. D. Wang, Y. Chen, Y. M. Ren, S. P. Zhang, Z. J. Chang and X. Y. Fu, “A Novel Protein Tyrosine Kinase NOK That Shares Homology with PlateletDerived Growth Factor/Fibroblast Growth Factor Receptors Induces Tumorigenesis and Metastasis in Nude Mice,” Cancer Research, Vol. 64, No. 10, 2004, pp. 3491-3499. doi:10.1158/0008-5472.CAN-03-2106
[2] J. Li, F. Wu, F. Sheng, Y. J. Li, D. Jin, X. Ding and S. Zhang, “NOK/STYK1 Interacts with GSK-3β and Mediates Ser9 Phosphorylation through Activated Akt,” FEBS Letters, Vol. 586, No. 21, 2012, pp. 3787-3792. doi:10.1016/j.febslet.2012.09.011
[3] K. S. Kimbro, K. Duschene, M. Willard, J. A. Moore and S. Freeman, “A Novel Gene STYK1/NOK Is Upregulated in Estrogen Receptor-Alpha Negative Estrogen Receptor-Beta Positive Breast Cancer Cells Following Estrogen Treatment,” Molecular Biology Reports, Vol. 35, No. 1, 2008, pp. 23-27. doi:10.1007/s11033-006-9047-1
[4] T. Amachika, D. Kobayashi, R. Moriai, N. Tsuji and N. Watanabe, “Diagnostic Relevance of Overexpressed mRNA of Novel Oncogene with Kinase-Domain (NOK) in Lung Cancers,” Lung Cancer, Vol. 56, No. 3, 2007, pp. 337-340. doi:10.1016/j.lungcan.2007.01.002
[5] D. M. Roder, “The Epidemiology of Gastric Cancer,” Gastric Cancer, Vol. 5 Suppl 1, 2002, pp. 5-11.
[6] B. Zilberstein, C. E. Jacob and I. Cecconello, “Gastric Cancer Trends in Epidemiology,” Arquivos de Gastroenterologia, Vol. 49, No. 3, 2012, pp. 177-178. doi:10.1590/S0004-28032012000300001
[7] P. Correa, M. B. Piazuelo and M. C. Camargo, “The Future of Gastric Cancer Prevention,” Gastric Cancer, Vol. 7, No. 1, 2004, pp. 9-16. doi:10.1007/s10120-003-0265-0
[8] T. Nakajima, “Gastric Cancer Treatment Guidelines in Japan,” Gastric Cancer, Vol. 5, No. 1, 2002, pp. 1-5. doi:10.1007/s101200200000
[9] J. Schiedel, A. Blaukat, S. Li, et al., “Matuzumab Binding to EGFR Prevents the Confomational Rearrangement Required for Dimerization,” Cancer Cell, Vol. 13, No. 4, 2008, pp. 365-373.
[10] Y. Matsui, M. Inomata, M. Tojigamori, et al., “Suppression of Tumor Growth in Human Gastric Cancer with HER2 Overexpression by an Anli-HER2 Antibody in a Murine Model,” International Journal of Oncology, Vol. 27, No. 3, 2005, pp. 68l-685.
[11] K. Fujimoto-Ouchi, F. Sekiguchi, H. Yasuuno, et al., “Antitumor Activity of Trustuzumab in Combination with Chemothempy in Human Gastric Cancer Xenograft Models,” Cancer Chemotherapy and Pharmacology, Vol. 59, No. 6, 2007, pp. 795-805.
[12] S. Y. Kim, H. P. Kim, Y. J. Kim, et al., “Traastuzumab Inhibits the Growth of Human Gastric Cancer Cell Lines with HER2 Amplification Synergistically with HER2/ Neu Overexpression/Amplification,” International Journal of Oncology, Vol. 32, No. 1, 2008, pp. 89-95.
[13] X. Ye, C. Ji, Q. Huang, C. Cheng, R. Tang, J. Xu, L. Zeng, J. Dai, Q. Wu, S. Gu, Y. Xie and Y. Mao, “Isolation and Characterization of a Human Putative Receptor Protein Kinase cDNA STYK1,” Molecular Biology Reports, Vol. 30, No. 2, 2003, pp. 91-96. doi:10.1023/A:1023934017174
[14] S. Chung, K. Tamura, M. Furihata, M. Uemura, Y. Daigo, Y. Nasu, T. Miki, T. Shuin, T. Fujioka, Y. Nakamura and H. Nakagawa, “Overexpression of the Potential Kinase Serine/Threonine/Tyrosine Kinase 1 (STYK 1) in Castrationresistant Prostate Cancer,” Cancer Science, Vol. 100, No. 11, 2009, pp. 2109-2114. doi:10.1111/j.1349-7006.2009.01277.x
[15] X. Ding, Q. B. Jiang, R. Li, S. Chen and S. Zhang, “NOK/ STYK1 Has a Strong Tendency towards Forming Aggregates and Colocalises with Epidermal Growth Factor Receptor in Endosomes,” Biochemical and Biophysical Research Communications, Vol. 421, No. 3, 2009, pp. 468-473. doi:10.1016/j.bbrc.2012.04.016
[16] Y. H. Li, Y. Y. Wang, S. Zhong, Z. L. Rong, Y. M. Ren, Z. Y. Li, S. P. Zhang, Z. J. Chang and L. Liu, “Transmembrane Helix of Novel Oncogene with Kinase-Domain (NOK) Influences Its Oligomerization and Limits the Activation of RAS/MAPK Signaling,” Molecules and Cells, Vol. 27, No. 1, 2009, pp. 39-45. doi:10.1007/s10059-009-0003-5
[17] T. Kondoh, D. Kobayashi, N. Tsuji, K. Kuribayashi and N. Watanabe, “Overexpression of Serine Threonine Tyrosine Kinase 1/Novel Oncogene with Kinase Domain mRNA in Patients with Acute Leukemia,” Experimental Hematology, Vol. 37, No. 7, 2009, pp. 824-830. doi:10.1016/j.exphem.2009.04.010
[18] Y. H. Li, S. Zhong, Z. L. Rong, Y. M. Ren, Z. Y. Li, S. P. Zhang, Z. Chang and L. Liu, “The Carboxyl Terminal Tyrosine 417 Residue of NOK Has an Autoinhibitory Effect on NOK-Mediated Signaling Transductions,” Biochemical and Biophysical Research Communications, Vol. 356, No. 2, 2007, pp. 444-449. doi:10.1016/j.bbrc.2007.02.154
[19] R. Moriai, D. Kobayashi, T. Amachika, N. Tsuji and N. Watanabe, “Diagnostic Relevance of Overexpressed NOK mRNA in Breast Cancer,” Anticancer Research, Vol. 26, No. 6C, 2006, pp. 4969-4973.
[20] K. A. Jackson, G. Oprea, J. Handy and K. S. Kimbro, “Aberrant STYK1 Expression in Ovarian Cancer Tissues and Cell Lines,” Journal of Ovarian Research, Vol. 2, No. 1, 2009, pp. 15-22.
[21] Y.-H. Li, Y.-Y. Wang, S. Zhong, Z.-L. Rong, Y.-M. Ren, Z.-Y. Li, S.-P. Zhang, Z.-J. Chang and L. Liu, “Transmembrane Helix of Novel Oncogene with Kinase-Domain (NOK) Influences Its Oligomerization and Limits the Activation of RAS/MAPK Signaling,” Molecules and Cells, Vol. 27, No. 1, 2009, pp. 39-45.

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.